Practical perspectives on recent data and FDA approvals supporting novel agents that target EGFR exon 20 insertion mutations in non–small cell lung cancer.
EP. 1: The Evolving Landscape of Molecular Testing for NSCLC
EP. 2: NSCLC: Overcoming Barriers to Testing and Molecular Profiling
EP. 3: EGFR Exon 20 Insertion Mutations as a Therapeutic Target in NSCLC
EP. 4: NSCLC: Standard Treatment Approaches for EGFR Exon 20 Insertion Mutations
EP. 5: NSCLC: Amivantamab for Patients With EGFR Exon 20 Insertion Mutations
EP. 6: NSCLC: Mobocertinib for Patients With EGFR Exon 20 Insertion Mutations
EP. 7: Key Differences Between Amivantamab and Mobocertinib in NSCLC
EP. 8: Other Agents Targeting EGFR Exon 20 Insertion Mutations in NSCLC
EP. 9: NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion Mutations
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.